Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1122 | 964 | 1122 | 1101 | 1431 | 2139 |
Fund Return | 12.2% | -3.6% | 12.2% | 3.26% | 7.43% | 7.9% |
Place in category | 298 | 588 | 298 | 320 | 77 | 49 |
% in Category | 43 | 81 | 43 | 63 | 21 | 14 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
RBC Canadian Dividend Fund Series I | 23.25B | 18.70 | 8.42 | 8.53 | ||
RBC Canadian Div Fund Series D CAD | 23.25B | 18.08 | 7.84 | 7.93 | ||
RBC Canadian Div Fund Series F CAD | 23.25B | 18.40 | 8.14 | 8.24 | ||
RBC Sel Gr Port Sr F CAD | 18.12B | 17.46 | 5.01 | 7.85 | ||
RBC Sel Gr Port Sr T5 | 18.12B | 16.29 | 3.96 | 6.75 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Mawer International Equity Fund Cla | 7.79B | 14.63 | 2.47 | 7.35 | ||
DFA International Core Equity Class | 3.48B | 12.45 | 5.10 | 7.16 | ||
RBC International Equity Fund D CAD | 3.08B | 11.90 | 2.98 | 7.61 | ||
PHN Overseas Equity D | 2.07B | 13.61 | -0.64 | 6.88 | ||
Renaissance International Eq CAD | 1.87B | 4.59 | -1.09 | 6.76 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 3.90 | 588.4 | +2.58% | |
Mitsubishi UFJ Financial | JP3902900004 | 3.20 | 1,906.5 | -0.60% | |
Taiwan Semicon | TW0002330008 | 3.15 | 1,135.00 | +1.34% | |
EssilorLuxottica | FR0000121667 | 3.12 | 254.90 | +1.96% | |
Hitachi | JP3788600009 | 2.87 | 3,929.0 | +4.13% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | BUY | Strong Buy |
Summary | Buy | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review